GKOS רווח נקי למניה (EPS TTM) Glaukos Corporation

This annual net income per share chart demonstrates the success of Glaukos Corporation (GKOS) as a flagship in glaucoma microsurgery with robust patent protection. High R&D costs and strict FDA oversight create significant barriers to entry for new players. Revenues are based on the supply of implants and drug delivery systems to clinics. The value of -2.95 captures the magnitude of this parameter.
Glaukos Corp. - פילוחים אנליטיים ומדדי מפתח (GKOS)

Net income per share over 12 months measures the actual return of each security, allowing an investor to isolate market volatility from fundamental value via the net income per share over the last four quarters. The current value of -2.95 reflects the financial efficiency of Glaukos Corporation, whose implementation of innovative microstents and pharmaceuticals in ophthalmology establishes an unrivaled standard for glaucoma treatment.